Home - Euro Ewing Consortium
Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with current treatment but there has been no improvement in this proportion for 25 years. Treatment is unsuccessful because chemotherapy fails to prevent the development of, or to effectively treat established, metastases.
The Euro Ewing Consortium is a coalition of clinical study groups bringing together the most active clinicians and scientists in Europe dedicated to improving survival from ES. The EU-funded project supported an integrated programme of investigator-driven, inclusive clinical trials that were rigorously designed, conducted, analysed and reported, and underpinned by complementary embedded translational research. Through collaborative working, the EEC provided ES patients with greater access to clinical trials, allowed efficient acquisition of knowledge and delivered clinically meaningful results that will contribute to improved survival from ES.
EEC strategy and priorities
The EEC Executive has approved the following strategy to direct the work of the EEC over the next three years (EEC strategy 2021 (pdf)).
The priorities for the EEC are:
- Better treatments
- Support global efforts – collaboration will benefit European patients and worldwide patients
EEC Newsletter - July 2021
The third newsletter of the new era of the EEC can be viewed here.
The EEC has established two local therapy working groups - one for surgery and one for radiation oncology.
EEC PA is an author on a Ewing sarcoma publication
Yasmin Uhlenbruch, EEC patient advocate and member of the EEC Executive has contributed to a review of Ewing sarcoma by Stefan Zöllner and colleagues. The EEC is very encouraged to see this level of active involvement of patient advocates in research and dissemination. The paper, 'Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives' was published in the Journal of Clinical Medicine.
Another step closer to liquid biopsies for ES patients
Eleni Tomazou and colleagues have shown that sequencing of cell-free DNA from liquid biopsies of ES patients is feasible and can be used for the detection, classification and monitoring of disease. This study was part-funded by the EEC EU FP7 grant and the paper 'Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden' was published in Nature Communications.
Watch our films on the EURO EWING Consortium here. Thanks to all those members of the ES community who took part.
Patient advocacy has been a large part of the EEC project since 2013 and here are some of our current patient advocates talking about how they have contributed to our research. Watch the video here.
Membership is open to those in Europe and outside of Europe who are active in ES research/ treatment or patient advocacy. Before applying, you must have attended at least one EEC meeting. To apply for membership of the EEC, please complete the online form, and send your CV and two nominations from current EEC members to email@example.com.
The American Society of Clinical Oncology (ASCO) conference was held virtually during 4 - 8 June 2021.
A downloadable version of the 2021 ASCO Annual Meeting Proceedings is now available and the abstracts for the sarcoma talks can be found here - ASCO sarcoma abstracts (pdf).
Links to abstracts and conclusions specific to Ewing sarcoma can be found here - ASCO Ewing sarcoma abstracts.
- SIOP Europe Annual Meeting - 26-30 April 2021, virtual meeting including the following sessions:
- 6th European bone sarcoma network meeting - Session 1 - Osteosarcoma (Thursday, April 29th, 14:15 - 15:45 CEST)
- ITCC / Bone sarcoma Expert Session (operational meeting - by invitation only) (Friday, April 30th, 10:00 - 12:00 CEST)
- 6th European bone sarcoma network / EuroEwing consortium meeting - Session 2 - Ewing sarcoma (Friday, April 30th, 14:15 - 15:45 CEST)